Lipid Metabolic Reprogramming in Tumor Microenvironment: from Mechanisms to Therapeutics

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2023 Sep 12

PMID 37700339

Authors

Hao-Ran Jin

Jin Wang

Zi-Jing Wang

Ming-Jia Xi

Bi-Han Xia

Kai Deng

Jin-Lin Yang

Affiliations

Soon will be listed here.

Abstract

Lipid metabolic reprogramming is an emerging hallmark of cancer. In order to sustain uncontrolled proliferation and survive in unfavorable environments that lack oxygen and nutrients, tumor cells undergo metabolic transformations to exploit various ways of acquiring lipid and increasing lipid oxidation. In addition, stromal cells and immune cells in the tumor microenvironment also undergo lipid metabolic reprogramming, which further affects tumor functional phenotypes and immune responses. Given that lipid metabolism plays a critical role in supporting cancer progression and remodeling the tumor microenvironment, targeting the lipid metabolism pathway could provide a novel approach to cancer treatment. This review seeks to: (1) clarify the overall landscape and mechanisms of lipid metabolic reprogramming in cancer, (2) summarize the lipid metabolic landscapes within stromal cells and immune cells in the tumor microenvironment, and clarify their roles in tumor progression, and (3) summarize potential therapeutic targets for lipid metabolism, and highlight the potential for combining such approaches with other anti-tumor therapies to provide new therapeutic opportunities for cancer patients.

Citing Articles

Statin Drugs Are Associated With Response to Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer.

Kristoff T, Evans S, Nayi P, Abousaud M, Goyal S, Liu Y Cancer Med. 2025; 14(5):e70718.

PMID: 40052634 PMC: 11886884. DOI: 10.1002/cam4.70718.

Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.

Suri C, Pande B, Suhasini Sahithi L, Swarnkar S, Khelkar T, Verma H Cancer Drug Resist. 2025; 8:7.

PMID: 40051496 PMC: 11883236. DOI: 10.20517/cdr.2024.164.

Metabolic reprogramming in cancer and senescence.

Zhang Y, Tang J, Jiang C, Yi H, Guang S, Yin G MedComm (2020). 2025; 6(3):e70055.

PMID: 40046406 PMC: 11879902. DOI: 10.1002/mco2.70055.

Aptamer based immunotherapy: a potential solid tumor therapeutic.

Mathavan S, Tam Y, Mustaffa K, Tye G Front Immunol. 2025; 16:1536569.

PMID: 40034705 PMC: 11873091. DOI: 10.3389/fimmu.2025.1536569.

Noncoding RNA-encoded peptides in cancer: biological functions, posttranslational modifications and therapeutic potential.

Tan S, Yang W, Ren Z, Peng Q, Xu X, Jiang X J Hematol Oncol. 2025; 18(1):20.

PMID: 39972384 PMC: 11841355. DOI: 10.1186/s13045-025-01671-9.

References

Zhong C, Fan L, Yao F, Shi J, Fang W, Zhao H . HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc. Tumour Biol. 2014; 35(5):4123-9. DOI: 10.1007/s13277-013-1539-8. View

Camarda R, Zhou A, Kohnz R, Balakrishnan S, Mahieu C, Anderton B . Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016; 22(4):427-32. PMC: 4892846. DOI: 10.1038/nm.4055. View

Veglia F, Tyurin V, Blasi M, De Leo A, Kossenkov A, Donthireddy L . Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. 2019; 569(7754):73-78. PMC: 6557120. DOI: 10.1038/s41586-019-1118-2. View

Shao C, Yang F, Miao S, Liu W, Wang C, Shu Y . Role of hypoxia-induced exosomes in tumor biology. Mol Cancer. 2018; 17(1):120. PMC: 6087002. DOI: 10.1186/s12943-018-0869-y. View

Talebi A, Dehairs J, Rambow F, Rogiers A, Nittner D, Derua R . Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. Nat Commun. 2018; 9(1):2500. PMC: 6021375. DOI: 10.1038/s41467-018-04664-0. View

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

Vaupel P, Kallinowski F, Okunieff P . Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989; 49(23):6449-65. View

Boedtkjer E, Pedersen S . The Acidic Tumor Microenvironment as a Driver of Cancer. Annu Rev Physiol. 2019; 82:103-126. DOI: 10.1146/annurev-physiol-021119-034627. View

10.

Wu H, Weidinger C, Schmidt F, Keye J, Friedrich M, Yerinde C . Oleate but not stearate induces the regulatory phenotype of myeloid suppressor cells. Sci Rep. 2017; 7(1):7498. PMC: 5548895. DOI: 10.1038/s41598-017-07685-9. View

11.

Porta C, Consonni F, Morlacchi S, Sangaletti S, Bleve A, Totaro M . Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs. Cancer Res. 2020; 80(13):2874-2888. DOI: 10.1158/0008-5472.CAN-19-2843. View

12.

Wang C, Shi M, Ji J, Cai Q, Zhao Q, Jiang J . Stearoyl-CoA desaturase 1 (SCD1) facilitates the growth and anti-ferroptosis of gastric cancer cells and predicts poor prognosis of gastric cancer. Aging (Albany NY). 2020; 12(15):15374-15391. PMC: 7467382. DOI: 10.18632/aging.103598. View

13.

Nistico C, Pagliari F, Chiarella E, Guerreiro J, Marafioti M, Aversa I . Lipid Droplet Biosynthesis Impairment through DGAT2 Inhibition Sensitizes MCF7 Breast Cancer Cells to Radiation. Int J Mol Sci. 2021; 22(18). PMC: 8466244. DOI: 10.3390/ijms221810102. View

14.

Kock A, Larsson K, Bergqvist F, Eissler N, Elfman L, Raouf J . Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth. EBioMedicine. 2018; 32:84-92. PMC: 6021299. DOI: 10.1016/j.ebiom.2018.05.008. View

15.

Schcolnik-Cabrera A, Chavez-Blanco A, Dominguez-Gomez G, Taja-Chayeb L, Morales-Barcenas R, Trejo-Becerril C . Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy. Expert Opin Investig Drugs. 2018; 27(5):475-489. DOI: 10.1080/13543784.2018.1471132. View

16.

Shindou H, Hishikawa D, Harayama T, Yuki K, Shimizu T . Recent progress on acyl CoA: lysophospholipid acyltransferase research. J Lipid Res. 2008; 50 Suppl:S46-51. PMC: 2674719. DOI: 10.1194/jlr.R800035-JLR200. View

17.

Reyes-Castellanos G, Abdel Hadi N, Gallardo-Arriaga S, Masoud R, Garcia J, Lac S . Combining the antianginal drug perhexiline with chemotherapy induces complete pancreatic cancer regression . iScience. 2023; 26(6):106899. PMC: 10250830. DOI: 10.1016/j.isci.2023.106899. View

18.

Zhang Q, Wang H, Mao C, Sun M, Dominah G, Chen L . Fatty acid oxidation contributes to IL-1β secretion in M2 macrophages and promotes macrophage-mediated tumor cell migration. Mol Immunol. 2017; 94:27-35. PMC: 5801116. DOI: 10.1016/j.molimm.2017.12.011. View

19.

Moon S, Huang C, Houlihan S, Regunath K, Freed-Pastor W, Morris 4th J . p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression. Cell. 2018; 176(3):564-580.e19. PMC: 6483089. DOI: 10.1016/j.cell.2018.11.011. View

20.

Beyaz S, Mana M, Roper J, Kedrin D, Saadatpour A, Hong S . High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. Nature. 2016; 531(7592):53-8. PMC: 4846772. DOI: 10.1038/nature17173. View